Tafinlar (Dabrafenib) Capsules


Medical Evidence TAFINLAR

Generic name : Dabrafenib.

Trade name : Tafinlar.

Manufacturer information :

Tafinlar is manufactured by Glaxo Smith Kline.

Tafinlar FDA Approval :

Tafinlar first approved May 29th, 2013.

Tafinlar Dosage form:

Capsules: 50 mg, 75 mg.

Tafinlar Indications and Usag e:


BRAF protein kinase inhibitor indicated as a single agent for unresectable or metastatic melanoma with BRAF V600E mutation, or in combination with trametinib for BRAF V600E or V600K mutations.

Tafinlar (Dabrafenib) availability in India

  • You could import this medicine against import permit on Patient Name.
  • Please contact ACT Lifesciences Private Limited for further information.